---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-113241"
form_type: "8-K"
ticker: null
cik: "0001693011"
company_name: "Inozyme Pharma, Inc."
filed_at: "2024-10-07T23:59:59+00:00"
generated_at: "2026-05-30T19:17:25.917600+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Inozyme Pharma appoints Erik Harris as Class II director effective October 3, 2024

## Summary
- Erik Harris, Chief Commercial Officer and EVP at Ultragenyx, appointed to Inozyme's Board as Class II director.
- Director compensation: $40,000 annual cash retainer, initial option for 56,000 shares (3-year vest), annual option for 28,000 shares.
- Mr. Harris has over 20 years of biopharma commercial experience including roles at InterMune, Genentech, and Bristol-Myers Squibb.
- Standard indemnification agreement entered into; no family relationships or transactions with Inozyme officers require disclosure.

## SEC filing metadata
- accession: 0000950170-24-113241
- form_type: 8-K
- cik: 0001693011
- company_name: Inozyme Pharma, Inc.
- filed_at: 2024-10-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1693011/000095017024113241/0000950170-24-113241-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1693011/000095017024113241/inzy-20241003.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-113241
- JSON: https://secwatch.observer/filing/0000950170-24-113241.json
- Plain text: https://secwatch.observer/filing/0000950170-24-113241.txt

## Key facts
- Executive change
  Erik Harris was appointed as Director at Inozyme Pharma, Inc..
  - Action: appointed
  - Role: Director
  source text: appointed Erik Harris as a director of the Company, effective October 3, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1693011/000095017024113241/0000950170-24-113241-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.